Please login to the form below

Not currently logged in
Email:
Password:

Roy Baynes joins Gilead’s oncology division

Former Amgen man to become senior VP, oncology therapeutics at the US biopharma company

Roy Baynes - GileadDr Roy Baynes has been appointed senior VP, oncology therapeutics at US biopharmaceutical company Gilead.

His appointment comes after a 10-year spell at Amgen, where he served as VP of global development and therapeutic area head of haematology and oncology.

“Roy has an extensive background in clinical practice, academic research and in cancer drug development,” said Dr Norbert Bischofberger, executive VP, R&D and chief scientific officer.

“Under his leadership, we are well positioned to advance our growing number of pipeline programmes targeted at both haematological malignancies and solid tumours.”

Baynes will report to Bischofberger as part of his new role leading Gilead's programme in oncology.

Baynes added: “Cancer research is an incredibly challenging and evolving field, but one with great opportunity and I look forward to working closely with the internal team and external collaborators as we seek to develop novel cancer therapies that address significant unmet medical needs.”

Prior to his role at Amgen, Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute at Wayne State University in Detroit.

He was also a professor of medicine, professor of oncology and director of the bone marrow transplant programme during his time at Wayne State.

20th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics